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Abstract
Background: Biomarker discovery studies have been moving the focus from a single target gene to a set of target
genes. However, the number of target genes in a drug should be minimum to avoid drug side-effect or toxicity. But
still, the set of target genes should effectively block all possible paths of disease progression.
Methods: In this article, we propose a network based computational analysis for target gene identification for multi-
target drugs. The min-cut algorithm is employed to cut all the paths from onset genes to apoptotic genes on a disease
pathway. If the pathway network is completely disconnected, development of disease will not further go on. The
genes corresponding to the end points of the cutting edges are identified as candidate target genes for a multi-target
drug.
Results and conclusions: The proposed method was applied to 10 disease pathways. In total, thirty candidate genes
were suggested. The result was validated with gene set enrichment analysis software, PubMed literature review and de
facto drug targets.
Keywords: Target gene identification, Disease pathway, Directed PPI, Pathway network, Min-cut algorithm
Background
Studies on biomarker discovery have been moving the
focus from single genes to multiple genes that interact
in a cell [1–4]. The recent drug development researches
are underway in this trend, because the single target ap-
proach may remain a certain possibility of disease pro-
gression since it may be developed along the other
paths. On the other hands, the multiple target approach
is expected to be more effective by simultaneously
blocking multiple paths of disease progression. However,
it is reckless to consider all possible combinations of
genes since it may be not only computationally intract-
able but also impractical. The number of genes to be tar-
geted should be limited since it will increase the
possibility of unwanted side-effect or toxicity which may
be caused by a member drug belonging to the
multi-targeted drug [5]. In a word, a multi-target drug
with the minimum number of target genes will be most
desirable. In this regard, the gene set should play a role
of blocking disease progression from onset genes to
apoptotic genes. To this end, the min-cut network algo-
rithm can be applied to a disease pathway network and
it will provide a minimum target gene set. There exist
many well-established implementations for the min-cut
algorithm [6]. Barabási emphasized the importance of
network-based approaches to human diseases in identi-
fying new genes for complex diseases [7]. A network
based computational analysis also can be used to en-
hance the efficiency of the drug development process.
Wu et al. proposed a computational approach that finds
drug targets by clustering networks through heteroge-
neous biomedical data that include genes, biological pro-
cesses, pathways, and phenotypes [8]. Considering that
the conventional means demand considerable cost and
time, the approach of Wu et al. (i.e., target gene identifi-
cation using available sets of biomedical data) would be
an effective pre-run process ahead of proteomic analyses
or in vivo tests. However, in the network of a gene set,
known inflows and outflows influence the interactions
between genes, and most pathway data include this kind
of directional information [9]. Because such biological
processes cannot be retrogressive, in silico methods
should reflect these directional relations. In particular,
for target gene identification, directional or causal infor-
mation can be more important because the states of
molecules change to innate directions and not to their
opposite states. However, in the aforementioned study,
the directional relations were not implemented on the
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network. Nevertheless, many studies have recently used
directed networks that incorporate biological pathways
[6, 10–13]. Chen et al. suggested a sub-pathway-based
approach for analyzing drug responses, which is more
computationally effective than when examining the en-
tire pathway [10]. However, this approach is also prob-
lematic in that other genes are ignored if excluded from
the subset of a pathway. Given a directed network of
genes, the well-established graph algorithms can be used.
By representing genes as nodes and directions as edges,
various biomedical issues can be intuitively explained.
To gain insights about disease progression, graph-cut al-
gorithms can be used to identify target genes. A graph
cut refers to the process of dividing nodes in a network
into two groups such that no path links one group with
another. Interesting studies have been conducted that
use graph-cut algorithms, including for the prediction of
protein functions, to address the consistency problem in
multiple sequence alignment, and for hippocampus seg-
mentation in MR images [14–16].
Results
In this study, we propose an applied graph min-cut
algorithm (Min-cut) for use with disease pathways in
identifying drug-targeted genes. A cut is defined as a
set of edges. The target genes we define here are
those linked by these edges. A cut on the pathway
network blocks the progression of a disease. Assum-
ing that all edges have the same weight value, the
minimum number of edges results in a minimum
number of linked nodes. Min-cut is the minimum cut
achieved with the smallest total weight of the edges.
Our motivation for employing Min-cut to this study
is as follows. Drug compounds can target one specific
or sometimes several genes. Csermely indicated that
multi-target drugs based on a network approach can
help systematic drug design [17]. A graph-cut algo-
rithm can search multiple target genes simultaneously
and thus meet the requirements of drug design. How-
ever, approximately 22,000 known human genes exist,
some of which may be a candidate target gene (CTG)
[18, 19]. It is nearly impossible to consider all pos-
sible combinations of disease genes [20–22]. In terms
of a graph cut on a pathway network, this means that
every cut can provide a multiple number of CTGs.
To circumvent this difficulty, we employ Min-cut to
limit the number of CTGs. The proposed method is
applied to 10 disease pathways including Alzheimer’s
disease and type 2 diabetes mellitus. To validate the
results of our experiments, we employ gene set en-
richment analysis (GSEA) software and review
PubMed literature and de facto drug targets reported
in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database.
Experiment on Simulation Data
We applied the proposed method to the simulation data.
Fig. 1(a) is the simulated network which was generated
with 45 nodes and 56 directed edges and Fig. 1(b) is to
plot degree distribution showing that the network is a
scale free network. In order to apply Min-cut algorithm,
we set source nodes (indexed 1,2,8) which have no in-
coming edges and sink nodes (indexed 13,20) which
have no outgoing edges. There are previous target iden-
tification approaches based on network analysis. The
simplest and conceptual reference is to count the degree
of edges to define the most important target genes on
the undirected graph, so called Undirected Degree
Centrality (U_DC). And Degree Centrality (DC) is
defined as the number of outgoing links incident upon a
node, while U_DC includes both incoming and outgoing
edges. And the Hubs Centrality (HC) are basically singu-
lar vectors of the adjacency matrix of the graph [23, 24].
The ratio of cut-edges via total edges was used as a per-
formance measure so that the method which minimizes
the edge disruption (cut edges) will be assessed as a
good target gene identification method. Fig. 1(c) shows
that the ratio of cut-edges from Min-cut is 0.9 and the
ration of connected edges of resulting top 6 nodes from
three centralities is 0.32, 0.23, and 0.63 respectively. We
got a result that the Min-cut based method can suggest
the minimum cut-edges by considering the disruption
impact on the connection (edge) of genes, rather than
the genetic changes of each node (gene).
Experiment on Real Data
Table 1 summarizes the real data that were used to
verify the proposed method: disease pathways, di-
rected PPI, and protein-drug relations. Disease path-
ways were utilized to construct initial pathway
networks and to set the role of genes, whether source
or sink. We collected 10 disease pathways from the
KEGG [25]. In order to extract unique results by
setting disease specific onset or apoptotic genes, we
selected one or more disease pathways involved in 6
different disease classes such as neurodegenerative
diseases, metabolic diseases, and cancer, so on.
(Details about disease specific genes are explained in
the description of Table 2.) The KEGG database pro-
vides a manually drawn pathway map. Details of the
10 disease pathways, pathway name/ID, corresponding
disease name/ID, and class of the disease, are listed
in bottom of Table 1. The total number of genes
involved in are 1208. For network augmentation, we
employed directed PPI, which was developed by [12]
to investigate intracellular signal transduction. Their
resulting network includes 2626 directional relations
between 1126 proteins.
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Table 1 Data description
Description
Disease pathway 10 pathways of 10 diseases including 1208 genes KEGG (http://www.Genome.Jp/kegg/)
Directed PPI 2626 directional relations between 1126 proteins (http://stke.sciencemag.org/)
Pathway name/ID Disease name /ID Disease class
Alzheimer’s disease/ hsa05010 Alzheimer’s disease (AD)/H00056 Neurodegenerative diseases
Type II diabetes mellitus/ hsa04930 Type 2 diabetes mellitus (T2DM) /H00409 Endocrine, metabolic diseases
Melanoma/ hsa05218 Malignant melanoma [17]/H00038 Cancer
Prostate cancer/ hsa05215 Prostate cancer (PC)/H00024 Cancer
Amyotrophic lateral sclerosis/ hsa05014 Amyotrophic lateral sclerosis (ALS) /H00058 Neurodegenerative diseases
Huntington’s disease/ hsa05016 Huntington’s disease (HD)/H00059 Neurodegenerative diseases
Prion diseases/ hsa05020 Prion diseases (PRION)/H00061 Neurodegenerative diseases
Primary immunodeficiency/ hsa05340 Common variable immunodeficiency (CVID) /H00088 Primary immunodeficiency
Renal cell carcinoma/ hsa05211 Renal cell carcinoma (RCC)/H00021 Developmental disorder, Cancer
Nonalcoholic fatty liver disease/hsa04932 Nonalcoholic fatty liver disease (NAFLD) /H01333 Endocrine, metabolic diseases
Fig. 1 The result of the proposed method on simulated scale free network. a directed scale free network. b the plot of degree distribution.
c result of performance comparison between the proposed Mincut based algorithm with peer methods, U_DC, DC, and HC
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Initial pathway networks were built from each of
the pathways. And the initial networks were aug-
mented for becoming denser so that there will be not
any technical problem when we apply Min-cut algo-
rithm to the networks. First of all, we collected direc-
tional information on protein interaction network
data (directed PPI) derived from the study of [12].
Then Genes that are not connected in the initial
pathway are connected if their relations are indicated
in the directed PPI. Therefore, edges in the initial
network are augmented with edges in the directed
PPI. Figure 2 shows the results of the pathway aug-
mentation. The left side of the figure represents the
toll of nodes and the other side represents the toll of
edges. Bars indicating the initial network are shaded
and outlined; those of the augmented network are
represented with solid bars. In the case of AD, the
number of connected nodes (genes) included in the
network was 31 (18%) and the number of edges was
24, thus resulting in a sparse network. However, after
network augmentation with directed PPI, the number
of nodes and edges were increased to 210 and 467%,
respectively. Across the 10 disease pathway networks,
the average rate of increase in the number of nodes
and edges was 207 and 454%, respectively. Not only
the number of connected nodes and edges, but also
additional information on the direction between
nodes complemented the initial network.
Table 2 lists the source (disease onset) and sink (apop-
totic) genes defined in each pathway. One or more genes
per pathway were manually selected from descriptions
or curated studies in KEGG. Every pair of genes (source,
sink) was fed to Min-cut. For example, the number of
source and sink genes for AD was two and three, re-
spectively, and experiments were run a total of six times.
This approach was similarly applied to the remaining
disease pathways. The combination of (source, sink) per
pathway is summarized in the last column of Table 2.
Source genes tend to be specified with each disease
pathway, such as APP for AD and Htt for Huntington’s
disease. APP is an integral membrane protein that is
expressed in many normal tissues, particularly in the
synapses of neurons. Sometimes APP forms a protein
basis on amyloid plaques, which are found in the brains
of AD patients [26]. And the HTT gene provides instruc-
tions for making a protein called huntingtin which ac-
tives highly in the brain playing an important role in
nerve cells (neurons) [27]. By contrast, sink genes such
as CASP3 are commonly involved in several pathways,
which thus classifies them as apoptotic genes. Apoptosis
is a form of programmed cell death that occurs in multi-
cellular organisms [28]. This means that CASP3 can be
a sink gene of several diseases such as AD, HD, and
NAFLD as shown in Table 2.
The pie charts in Fig. 3 show the results of CTGs
identified by Min-cut. Note that the number of runs was
different for each disease pathway. These different run
proportions to the total number of runs should be con-
sidered. The number in parentheses indicates the num-
ber of occurrences of that gene during Min-cut runs for
every combination of (source, sink) genes. The higher
the occurrence rate, the more significant was the gene as
a CTG. For example, in the case of AD, PSEN1 occurred
twice as many times as CTG during six runs. The pro-
portion of PSEN1 in AD was 33.3% (=2/6 × 100) The
most frequently occurring CTGs in AD were PSEN1,
PSEN2, and SNCA. In addition, their occurrence rates
were all 33.3%. However, in the case of primary im-
munodeficiency (CVID) and renal cell carcinoma (RCC),
we could not identify CTGs because there was no con-
nection between source and sink genes.
As a representative example, Fig. 4 shows the resulting
networks of Alzheimer CTGs with source and sink genes.
Solid edges in Fig. 4(a) are from pathway data of 24
relations between 31 genes of 171 total disease-related
genes (connected nodes = 18%). The dotted edges indicate
directed PPI. In this example, 112 relations between 65
genes were augmented. Figure 4(b) shows the results of
Table 2 Source and sink genes
ID Source genes Sink genes # of (source, sink) combination
AD APP; CAPN1 CASP3; APBB1; MAPT 6
T2DM INS; INSR GLUT4 2
MEL GF; NRAS; BRAF CCND1; CDK4 6
PC GF; PTEN; NKX3–1; CDKN1B E2F1; TP53; BCL2; CASP9; BAD; FOXO1; MTOR 28
ALS SOD1 MAP3K5; CASP3; NEFL; NEFM; NEFH 5
HD Htt; GRM5 CASP3; ITPR1 4
PRION PrPc PKA 1
CVID RAG1; RAG ICOS 2
RCC HGF; MET; EPAS1 SLC2A1; VEGFA; TGFB1; PDGFB; GFA 15
NAFLD IL6; TNF; INS; LEP; ADIPOQ; FASLG CASP3; CASP7; MAPK8 18
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Min-cut applied to the augmented network. In the figure,
APP and CASP3 were set as a pair of (source, sink).
Min-cut successfully disconnected the network with min-
imal effort; five edges were cut. Along the respective
edges, five CTGs were identified: PSEN1, CASP8, SNCA,
PSEN2, and APAF1A. Those are marked with solid circles.
And Fig. 5(a) is Illustration for cut-edges and the CTGs in
AD pathway from KEGG an illustration for cut-edges and
CTGs in the AD process sourced from KEGG pathway.
As it shows, SNCA plays an important role changing
amyloid beta to the senile plaques which are extracellular
deposits of amyloid beta in the grey matter of the
brain. Fig. 5(b) shows that the ratio of cut-edges from
Min-cut is 0.15 and the ration of connected edges of
resulting top 7 nodes from three centralities is 0.32, 0.39,
and 0.69 respectively.
To verify CTGs identified in our experiments, we
conducted GSEA, and reviewed PubMed literature and
de facto drug targets reported in the KEGG database.
In this study, we provide validation results for AD. Fig-
ure 5. shows a comparison of the two sets (AD and
control). We found that most genes involved in the
KEGG AD pathway were DEGs of the AD phenotype in
GSEA. This indicates that our obtained initial network
from the AD pathway is a reasonable and an efficient
means to find markers. Each of the AD CTGs that we
identified are shown in the different panels in Fig. 6.
where The upper panel (a) shows ES patterns for the
control: a KEGG notch signaling pathway containing 34
genes. The overall profile of the result indicates that ES
is positively correlated with a phenotype, the maximum
deviation of ESs from zero reaches 0.567, and the nom-
inal p value is 0.010. By contrast, the lower panel (b)
shows ES patterns for AD: a KEGG Alzheimer’s disease
pathway containing 140 genes. The overall profile of
the AD result indicates that ES is negatively correlated
with a phenotype, the maximum deviation of ESs from
zero reaches − 0.576, and the nominal p value is 0.008.
The two patterns are significantly different, and a sud-
den increase in ES in the lower panel provides evidence
Fig. 3 CTGs. Source and sink genes appearing in Table 2 are
excluded from these charts
Fig. 2 Network augmentation results
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that the genes in the AD pathway are significant. In our
AD CTGs, four genes are located at the rightmost side
of the graph, and thus appear to be target genes: SNCA
(ES: -0.415), CDK5 (ES: -0.402), CDK5R1 (ES: -0.320),
and PSEN1 (ES: -0.094).
The following are typical findings from previous stud-
ies on CTGs of AD. The CTGs of AD in Fig. 3 were de-
rived from PubMed literature. More results are provided
in Table 3. SNCA: Non-Aβ component of AD amyloid
precursor SNCA gene may contribute to an increased
risk of AD. SNCA gene polymorphism may be associ-
ated with an increased risk of AD [29, 30]. CDK5:
Cyclin-dependent kinase 5 is reported to intimately asso-
ciate with the process of the pathogenesis of AD. CDK5/
CDK5R1 protein kinases involved in abnormal tau
phosphorylation in AD. Tau proteins are widely known
to be associated with dementias of the nervous system
such as Alzheimer’s disease and Parkinson’s disease [31–
33]. PSEN1: Mutations in the presenilin 1 gene are the
most frequent cause of familial AD. There are reports
about PSEN1 mutations in various species including
Turkish, Chinese, and Korean [34–36].
Among the CTGs we discovered and as shown in Fig. 3
are de facto drug targets. The following target genes and
drugs are also listed in Table 4: PSEM1 for Alzheimer’s
disease, INSR for Type II diabetes mellitus, MAP2K for
Melanoma, and AR for prostate cancer. These have been
already developed as drugs to treat the diseases in
practice. The rest of our CTGs also have potential to be
biomarkers as drug targets.
Fig. 4 Visualization of resulting networks from Min-cut on the pathway of AD. a AD pathway network constructed with gene-gene interactions in
the AD pathway (solid line) and directed PPI (dotted line). b Results of CTGs by Min-cut
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Discussion
Our study is based on the notion that target genes inter-
rupt the progress of a disease. The resulting CTGs of
our Min-cut are points at which the flow from disease
onset genes to apoptotic genes can be cut. The visual-
ized CTGs on the pathway network can help in under-
standing the mechanisms involved in disease
progression and the roles that CTGs play therein. And
the proposed method offers new insights into disease
treatment and drug development. The CTGs can be rec-
ommended as preferential subjects to improve the treat-
ment of diseases and drug design. Although CTGs have
not been fully validated, we believe that they have the
potential to be primary drug targets from of a consider-
able number of genes.
Conclusions
In this study, we proposed the pathway Min-cut algorithm
for target gene identification. It is assumed that if the net-
work of a disease pathway is disconnected, development
of the disease will not continue. To find points along the
pathway that can be “cut,” while performing this task at a
minimal cost, Min-cut algorithm was developed. We then
applied it to a network augmented with additional infor-
mation on gene-gene relations, including the causalities
between them. Given source and sink genes, the proposed
algorithm found an edge set that blocks every flow from a
source to a sink gene. The candidate genes were validated
through diverse means, namely, gene expression profiling
by GSEA, the findings from various studies, and existing
drugs. This work can be complemented if the biological
domain produced a greater number of novel discoveries in
areas such as gene-gene relations, disease pathways, gene
expression and mutation, and so on.
Methods
Figure 7 illustrates the overall procedure of our study. First,
a network is composed of a disease pathway. Each node in-
dicates disease related genes and a directed edge between
two different genes indicates that one gene may have bio-
logical changes in that direction. And then the initial net-
work augmented with directed PPI information to endow
causality on flows on the network, as shown in Fig. 7(a)
[12]. Solid black edges are from pathway data and dotted
blue edges are from directed PPI data. Second, as shown in
Fig. 7(b), source and sink genes are chosen, where source
Fig. 5 a Illustration for cut-edges and the CTGs in AD pathway from KEGG. b comparison of the resulting CTGs on AD with previous network-
based essential gene identification methods, Degree Centrality and Hubs method for AD and ALS
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genes may be considered responsible for the onset of a dis-
ease and sink genes may lead to apoptosis. One or more
genes per pathway were manually selected from descrip-
tions or curated studies in KEGG. Every pair of genes
(source, sink) was fed to Min-cut. Finally, as shown in Fig.
7(c), Min-cut finds the smallest sum of edges necessary to
disconnect (i.e., “cut” the pathway of) a disease-onset gene
and an apoptotic gene [37, 38]. The resulting multi-genes,
Table 3 The list of validation results on PubMed literatures
Disease name Candidate Target Genes PMID
AD PSEN1 24927704, 24718101, 24928006, 25045597, 24416243, 20388456, 21501661, 25595498, 22503161,
18437002, 24906965, 22618995
CASP8 28985224
CDK5 28714390, 23816988
GSK3B 24101602, 25420549, 20576277, 18932008, 18852354, 17028556
PSEN2 24927704, 25104557, 25045597, 24838203, 26203236, 20164579
SNCA 24777780, 27567856, 27184464, 18322368
APAF1 –
CDK5R1 21130128
T2DM IRS1 24612564, 21917432, 24584551, 21834909, 19734900, 14633864
PIK3CA 28934129, 28477532
MEL MAP2K1 28881731, 23174022, 22197931
MAPK1 24468268, 24158781
EGFR 29311018, 29121185
PIK3R2 –
ARAF 24962318
PIK3CA 28972077, 26343386
PC AR 29460922; 29464071; 29462692;
EGFR –
GRB2 25153383;
PIK3R2 26677064;
NFKB1 –
AKT3 25153383; 28624527; 28150530;
CCND1 29142597;
CDK2 29323532; 27819669;
AL CASP9 –
PPP3CA –
BCL2 24737943, 21678416, 21624464
MAPK14 –
C16844 –
HD GNAQ –
PRION STIP1 –
NAFLD IL6R; –
TNFRSF1A; –
TRAF2; –
INSR; 29325294, 29254185
LEPR; 27470889, 27257426, 26965314
PPARA; 29327584; 28077274;
FAS 29345914;
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which are linked by the cut edges, are identified as CTGs.
Details of the method are provided in the following
subsections.
Disease pathway network and augmentation
In our method, each disease pathway is represented
as a network G = (V, E) that consists of genes as nodes
V and relations between genes as edges E. In this ini-
tial network, a significant number of nodes are not
connected. Therefore, the network is augmented with
biological domain knowledge and is endowed with
causality on its edges. There are some technical bene-
fits to this network augmentation. First, the network
becomes denser; if the network is sparse, applying
Min-cut is difficult. Second, directionality reduces the
solution space by eliminating unnecessary paths from
the network. The directional information on protein
interaction network data (directed PPI) is derived
from the study of [12]. Genes that are not connected
in the initial pathway are connected if their relations
are indicated in the directed PPI, as shown in Fig. 7
(a). Therefore, edges in the initial network E are aug-
mented with edges in the directed PPI E
!
.
Source and sink genes
In the augmented network, defining sets of source nodes
S and sink nodes T, as shown in Fig. 7(b), is required. In
the case of source nodes, some genes can be found in
the KEGG description or the well-known study in
PubMed. They tend to be located at the beginning of the
pathway because the pathway describes sequential
changes of state from normal to abnormal. Although the
source genes have a normal status, they may cause the
disease. For example, amyloid precursor protein (APP),
which appears at the beginning of the Alzheimer’s disease
(AD) pathway, can be defined as a source node s ∈ S.
However, sink genes are generally found at the end of the
pathway in which apoptosis or a disorder status are de-
scribed. In several pathways including the AD pathway,
CASP3 can be defined as a sink node t ∈T. This protein is
a member of the cysteine-aspartic acid protease (caspase)
family. Sequential activation of caspases plays a central
role in the execution-phase of cell apoptosis.
Pathway partitioning using min-cut
The proposed method employs a Min-cut algorithm
[37, 38] to find CTGs. We assume that cutting an edge
with direction from one gene to the other means that
Table 4 Validation of de facto drug targets
ID Target proteins Drug
AD PSEN1 (HSA:5663) Begacestat (D08869) /Tarenflurbil (D09010) /Semagacestat (D09377) /Avagacestat (D09869)
T2DM INSR (HSA:3643) Insulin (D00085) / etc. 19 insulin related drugs
MEL MAP2K (HSA:5604) Cobimetinib (D10405) /Cobimetinib fumarate (D10615)
PC AR (HSA:367) Testosterone (D00075) /Flutamide (D00586) /Bicalutamide (D00961) /Nilutamide (D00965) /Enzalutamide (D10218)
Fig. 6 Gene set enrichment analysis: a Control: KEGG notch signaling pathway. b AD: KEGG Alzheimer’s disease pathway
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blocking the change from one gene to the other. That
is, we define genes connected to the cut edges as
CTGs. The ultimate goal of the algorithm is to find a
set of genes connected to the cut edges. The number
of edges cut by Min-cut can be multiple if multiple
paths exist from the source to the sink. The algorithm
minimizes the number of cut edges, technically to im-
prove efficiency of the marker development process and
biologically to avoid unwanted side effects by selecting too
many genes together. In this process, the genes connected
to the cut edges become candidate target genes because
the multiple cut edges completely disconnect the onset
gene (source) from the apoptotic gene (sink). For example,
when there are two nodes (genes) A, B and a connected
directional edge (AB) from A to B, cutting (AB) indicates
biologically blocking gene A to be transformed to gene B.
This is what we traditionally try to do in the targeted
treatment and drug development. In short, cutting a cer-
tain edge refers to developing treatments by targeting two
genes of the cut-edge. Once source S and sink nodes T are
determined in the network, Min-cut finds the edges min-
imizing the following functional: Minimize cðS;TÞ
¼Pði; jÞ∈Ewijeij ¼
P
ðu;vÞ∈ðS;TÞ∩Ewuvwhere c(S,T) denotes
the s-t cut capacity, which is the sum of edge
weights, wijeij. The value of wij is large if the connec-
tion is strong, and vice versa. In addition, eij is 1 if
nodes i and j are connected, and 0 otherwise. Note
that edges in the pathway network are not weighted,
and thus eij is ignored. Regarding source and sink
genes, the capacity becomes the sum of wuv, where
(u, v) ∈ (S,T). In our pathway application, the cut
edges found by Min-cut may be regarded as the
border of disease progression from normal to abnor-
mal status. Then, it is assumed that the genes con-
nected by the cut edge become a set of CTGs. Figure
6(c) illustrates the idea of cutting edges at the mini-
mum capacity. Figure 8 provides the pseudo-code giv-
ing further details.
Gene set enrichment analysis
We interpreted the resulting CTGs by profiling gene
expression. GSEA is a computational method that in-
dicates whether predefined gene sets (pathway) reveal
Fig. 7 Proposed Method: a Disease pathway network augmentation with directed PPI, b source and sink genes, (c) Min-cut for candidate target
gene identification
Fig. 8 Pseudo-code for pathway Min-cut
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statistically significant, considering the two pheno-
types [39, 40]. Much research has been conducted
based on the assumption that differentially expressed
genes (DEGs) may be potential biomarkers [41–43].
In case of the AD, a gene expression dataset
(GSE1297) was obtained from GEO that contains
13,321 gene expression values for two classes, one for
AD and the other for a control. GSEA provides a
ranked list that is based on the gene differential ex-
pression between the classes for the entire range of
genes. More importantly, an enrichment score (ES) is
calculated by moving down the ranked list and in-
creasing a running-sum statistic whenever a gene in a
set is encountered, while decreasing it when genes
are not in an a priori defined set of genes such as a
pathway. This will then reflect the degree to which a
set is overrepresented at the extremes (top or bottom)
of the entire ranked list. For details on GSEA, see the
study of [39].
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